Arthritis&Rheumatology
Page 37 of 42
Supplementary Table l.Levels ofpentraxin 3(PTX3)and flbrOblast growi factor-2(FGF2)in
systemic sclerosis(SSC)patients grouped by the presence or absencc of each organ lllvolVement
FGF2
PTX3
Mcan tt SD
og/mL)
８
７
１
４
４
４
４
４
1.0
４ １
１ ７
11.7± 8.2
５ １
１ ７
4.8± 3.5
12.1上 9.6
１
７
Absence
0.6
0.9
extenslvc
76
４
１
4.7± 2.6
５ １
１ ７
Presclllce
ILD
11.7■ 9.4
11.9■ 9.3
0.5
0.3
10
２
４
4.6± 3.4
２
４
Absence
5.0■ 3.2
14.6± 9.4
0.13
９ ６
３ ４
４
４
ILD
Presencc
Lowl
Highl
７
<0.001
<0.001
SD
(pg/mL)
４
８
4.3± 2.8
Abscncc
NIlean■
１
9.4± 4.3
６ ０
１ ７
DU
Presencc
Lowl
Highl
12.1■ 9.6
stage
８ ７
１ ６
５
０
８
０
８
８ ７
３ ４
′” ●４
５ ３
１
７
４
８
９
７
11.9± 9.5
0.06
１
1
12.1± 9.4
85
0.4
offlevels for PTX3 and FGF2 were 3.88 ng/mL alld 9.82 pg/mL,respccively.
DU:digital ulcer,ILD:illterstiial lung disease,PAH:pulmonary arte
gastrointestinal
Viley&Sons
Joれ れヽ
al hypertension,GI:
４
８
1.0
6.4± 4.8
lCut―
４
８
0.6
4.8± 3.3
５
８
Abscncc
4.6± 1.5
15.1■ 5.6
１
１
Rcnal
involvcmcnt
Prcscnce
0.02
0.09
0,7
0.8
２
８
4.8± 3.4
Abscnce
︲
８
4.4圭 2.0
involvcmcnt
0.09
３
５
Lowcr GI
Prcscncc
13.2± 9.9
10.6± 8.6
0.09
0.07
６
4.3± 3.0
1.0
0.9
０ ５
４ ４
Abscncc
３
８
２
８
5.2± 3.5
２ ４
５ ３
involvement
Presencc
13.2■ 10.9
11.9± 9.3
0.2
0.08
Uppcr GI
4.7圭 3.2
８
７
Abscncc
involvemellt
３
８
Hcart
<0.001
<0.001
0.06
6.3生 4.1
３
12.5± 8.9
0.006
Presence
8.1± 12.3
９
７
4.5± 3.0
Absencc
６
6.8 EL 4.6
５ １
１ ７
PAH
Prcsencc
1.0
0.9
1.0
0.4
1.0
Arthritis&Rheumatology
Supplementary Table 2.Mulivariate analysis for identiゥ
Page 38 of 42
ing independent factors affecing the
prcsence ofE)U
Multiva
Univariatc
Variあ les
品D
の
Age at SSc onsct
７ ３ ９
０ ０ ０
Fcmale
Age at entry
P
RIultivariate
atc
(MOdel#1)
跳D
の
(NIIOdcl#2)
P
轟⊃
ρ
1.60
(0.20-13.0)
0.98
(0.95-1.02)
1.00
(0.96… 1.04)
Discase dLlration from tllc
frst non― RP
symptoms
E)iscase duration iom the
flrst RP
dcSSc
0.07
0.10
0.04
RP
1.0
Previous history ofI)U
<0.001
①,;11っ
0.99
08
(0.90-1.09)
03
(0.04-2.45)
0.7
0.98
(0.90‐ 1.07)
1.04
(0.99-1.09)
。 01:l①
0.33
0.3
0.37
(0.06-2.28)
NDl
。 の
,:lち
<0剛
61.7
(7.09‐ 537)
く0.001
45.6
(8.16… 254)
Organ involvement:
ILD
0.7
ILD,extensivc stagc
0.6
PAH
0.9
Hcart involvcmcnt
0.4
Upper GI
0.02
Lowcr GI
0.8
Renalinvolvcmcnt
1.0
1.22
(0.45… 3.32)
0.63
(0.14-2.90)
0.95
(0.20-4.47)
2.15
(0.42‐ 10.9)
2震 :.っ 04
。
2.46
(0.38‐ 16.0)
0.15
3.30
(0.64… 17.0)
1.31
(0.15-11.4)
blDl
Autoantibodics
Anticcntromere
0.3
0.06
Anti‐ topo I
1.76
(0.65-4.82)
:;L2)
(0.9ξ
1.0
NDl
Anti¨ Th/To
1.0
NDl
Anti― RNAP
0,7
Allti―
Anti―
UlRNP
III
U3RbIP
Anti― Ktl
°
0・ 4
l.54
(0.17-13.7)
1.0
NDl
1.0
NDl
」ohn
Wiley&Sons
8.01
(1.13-57.1)
0.09
4.29
(0.82… 22.6)
Arthritis&Rheumato:ogy
Page 39 of 42
Q6 。
Corticosteroids
3:」
<a剛
PTX3
FGF2
lo
_
0.3
」亀
。
っ
(0.98::λ
3)
0.04 (1.0誌 T:02)
PTX3/FGF2 ratio
Model#1灘 opted
PTX3 and FGF2 as varlables,whereas model#2 adopted PTX3AFGF2 ratio instead.
10R was unable to calculate because one of4 columns in the 2 x 2 table was``0".
OR:odds ratio,CI:confldence interval,ND:not detellllincd,RP:Raynaud's phenome■ on,dcSSc:
dimuse cutaneous SSc,DU:digital ulcer,ILD:nterstitial lullg disease,PAH:pulmonary arte
al
hypcrtension,GI:gastrointestinal,topo I:topoisomerase I,RNAP:RNA polymerasc
John Wiley&Sons
Arthritis&Rheumatology
Supplementary Table 3。 Mult
Page 40 of 42
ariatc analysis for identifying independent factors affecing the
presencc ofPAH
Unlvanatc
Variablcs
OR
1.0
Age at SSc onset
0.3
0.10
Agc at cntry
E)iscasc duration■ om thc
flrst non‐ RP
symptolns
(0.99-1.08)
(0。
RP
0.7
Prevlous history ofI)U
1.0
1.03
1.10)
97‐
1.04
(0,99-1.08)
2.26
(0.63-8.07)
1.02
(0.98-1.08)
1.44
(0.27‐ 7.76)
６ ６
0.2
ttn
θ
1.03
０ ０
lcSSc
P
(0.98… 1.06)
0.3
0.11
ttD
θ
l.02
４ ７
frst RP
鮮 odcl#2)
NDl
０ ０
Discasc duration■ om the
ヽlultivanatc
(NIIOdCl#1)
P
f95%CI〕
Fcmalc
Muluvanate
1.01
(0.96‐ 1.07)
1.59
(0.26… 9.67)
0.69
(0.08-6.21)
NDl
Organ involvement:
0.95
DU
0.9
ILD
0.7
ILD,extensive stage
0.8
Hcart involvelnent
1.0
NDl
Upper GI
1.0
NDl
Lowcr GI
1.0
NDl
Renal involvement
1.0
NDl
(0.20¨ 4.47)
1.19
(0.48‐ 2.97)
1.18
(0.37‐ 3.79)
Autoantibodies
Anticcntromcrc
0.07
Anti― topo I
Anti‐
0.2
UlRNP
0.14
Anti‐ Th/To
1.75
(0.70‐ 4.37)
0.25
(0.06-1.14)
2.21
(0.78-6.29)
1.0
blDl
1.0
NDl
Anti―
RNAP
Anti―
U3RNTP
1.0
NDl
Anti―
Ku
1.0
NDl
ⅡI
0.3
3ohn Wiley&Sons
0.37
(0.06-2.24)
0.3
0.37
(0.06-2.37)
Page 41 of 42
Corticosteroids
Arthritis&Rheumato:ogy
02 。
み
″
生
ち
⇒
PTX3
FGF2
α
∞2温 1)の
α
∞ C81:L幼
PTX3/FGF2 ratio
ヽlodel#l adopted PTX3 and FGF2 as variables,whereas lnodel#2 adopted PTX3月
10R was unable to calculate because one of4 collllnIIls in the 2 x 2 table was“ 0".
鋤Ю
鋭 軋0謂 :0の
FGF2 ratio instead.
ORl odds ratio,CI:conidencc intcrval,ND:■ ot detel.llilled,RP:Raynaud's phcnomcnon,dcSSc:
al
dittse cutancous SSc,DU:digital ulccr,ILD:mtcrstitial lung disease,PAH:pulmonary arte
hypertension,GI:gastrointcstmal,topo I:topoisomerase I,RNAPI RNA polymerase
」ohn
Wiloy&Sons
Arthritis&Rheumatology
Supplementary Table 4.Mult
Page 42 of 42
aritte analysis for identitting faCtOrs predicing hture
dcveloplllent ofDU
Multivariate
Unlvanate
Variables
ttD
θ
Age at cntry
P
ttD
θ
P
HR
(95%CI〕
0.47
(0.14‐ 1.64)
0.98
(0.95… 1.01)
0.99
(0,96… 1.03)
E)iscasc duration from the
flrst non‐ RP
２ ３ ７
Age at SSc onsct
０ ０ ０
Fcmale
ヽ4ultiva atc
OdCl#2)
(ゝ 江
(MOdel#1)
symptolns
E)iscase duration from the
flrst RP
0.16
0.4
０．
０
RP
２
０ ‘
dcSSc
0.94
(0.87-1.02)
0.3
0.96
(0.88-1.05)
0.4
0.96
(0.89‐ 1.05)
0.97
(0.92‐ 1.03)
3.09
(1.22‐ 7.82)
0.2
2.10
(0.62-7.13)
0.16
2.45
(0.71-8.76)
NDl
Organ involvement
ILD
0.7
ILD,extcnsivc stagc
0.6
Hcart involvclllCnt
0.7
Upper GI
0.15
Lower GI
0.4
Rcnalinvolvcmcnt
0.8
l.21
(0.48-3.04)
1.35
(0.45-4.11)
1.61
(0.21-12.2)
2.15
(0.77-6.05)
1.94
(0.44… 8.48)
NDl
Autoantibodies
Anticentromcrc
0.08
Anti― topo I
Anti―
0.2
UlRNP
Anti¨ Th/To
0.13
0.4
Anti¨
RNAP
Anti―
U3RhlP
0.7
Corticostcroids
0.2
ⅡI
0.6
1.82
(0.72‐ 4.58)
2.32
(0.91-9.89)
0.21
0.3
1.84
(0.53… 6.32)
(0.03-1.61)
NDl
l.64
(0.22-12.4)
NDl
l.99
(0.65‐ 6.07)
PTX3
0.001
FGF2
0.08
John Wiley 84 Sons
1.25
(1.09-1.42)
0.95
(0.90-1.01)
0.6
1.41
(0.41‐ 4.80)
Page 43 of42
Arthritis&Rheumato:ogy
0.003 (1.0蕊
PTX3/FGF2 ratio
Ψ:01)
NIIodcl#l adopted PTX3 and FGF2 as variablcs,whereas IInodel#2 adopted PTX3/FGF2 ratio instead.
lHR was unablc to calculatc bccause one of4 colullllns in the 2 x 2 tablc was“
0".
HR:hazard ratio,CI:confldence mtelval,NDi not detell■ ■
ined,RP:Raynaud's phcnomenon,dcSSc:
di3Mse cutaneous SSc, ]DU: digital ulcer, ILD: interstitial lung disease, PAI‐ I: pulllnonary arterial
hypertension,GI:gtttrointestinal,topO■ tOpoisomerase l,RNAP:RNA polymerase
John Wiley&Sons

7. exploded views and parts list - Recambios, accesorios y repuestos

FAX:0531-23-3006